ALDH2 and diabetic neuropathy: Chronic empagliflozin administration effectively decreased renal oxidative stress, tissue inflammation, and improved insulin sensitivity in diabetic rats via mechanisms including decreased methylglyoxal levels in diabetic neuropathy, reduced AGE/RAGE signaling, improved •NO/cGMP signaling, upregulated redox regulated enzyme mitochondrial aldehyde dehydrogenase (ALDH-2), and decreased epigenetic activation of Nitric Oxide Synthase (NOS2) and IFNγ [28,165].